Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
1R43GM077724-01
Award Id:
80562
Agency Tracking Number:
GM077724
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
MOLECULAR DESIGN INTERNATIONAL, 99 South Second Street, Suite A-141, MEMPHIS, TN, 38103
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
WILLIAM PURCELL
(901) 454-0797
purcell@moleculardesign.com
Business Contact:
WILLIAM PURCELL
(901) 529-1919
PURCELL@MOLECULARDESIGN.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A major feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Recent studies from our laboratory have shown that topical treatment of diabetic rats with RA improves the healing of subsequently-induced abrasion wounds. Based on this, we have proposed the prophylactic use of RA as a way to improve structure/function in diabetic skin at risk for ulcer formation. A potential drawback to this strategy is skin irritation. If retinoid use in diabetic skin provokes irritation, this could result in non-use (as is does in other groups of retinoid users). Additionally, if the degree of irritation is too great, the irritation could counter-act the beneficial effects of retinoid treatment in the at-risk skin. The overall goal of the proposed studies is to determine if topical pretreatment of skin with MDI 301 will, like RA itself, improve healing of subsequently-induced wounds but do so without provoking irritation. If it can be shown that MDI 301 is as effective as RA without the negative consequence seen with RA use, it will provide a better agent for development as a chronic wound preventative. To achieve our overall goal, we will compare the effects of topical MDI 301 treatment with topical RA on dermal structure/function in streptozotocin diabetic (STZ-D) rats and compare healing of abrasion wounds in control rats, STZ-D rats and STZ-D rats that have been pretreated with topical RA or topical MDI 301.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government